Author

J. A. Nilsson

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 6

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Organism:human· 4 Organism:mouse· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2

Frequent Co-Authors

L. M. Nilsson· 5 shared L. Ny· 4 shared R. Olofsson Bagge· 3 shared S. Alsen· 3 shared V. R. Sah· 3 shared E. M. Forsberg· 2 shared H. Jespersen· 2 shared J. Karlsson· 2 shared

Activity by Year

2019-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

L. M. Nilsson

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Patient-derived xenografts and single-cell sequencing identifies three subtypes of tumor-reactive lymphocytes in uveal melanoma metastases

J. W. Karlsson, V. R. Sah, R. Olofsson Bagge, I. Kuznetsova, M. Iqba, S. Alsen, S. Stenqvist, A. Saxena, L. Ny, L. Nilsson, J. A. Nilsson

bioRxiv · May 16, 2023Cancer Biology

Treatment with anti-HER2 chimeric antigen receptor tumor-infiltrating lymphocytes (CAR-TILs) is safe and associated with antitumor efficacy in mice and companion dogs

E. M. Forsberg, R. Riise, S. Saellstrom, J. W. Karlsson, S. Alsen, V. Bucher, A. E. Hemminki, R. Olofsson Bagge, L. Ny, L. M. Nilsson, H. Ronnberg, J. A. Nilsson

This study evaluates the safety and antitumor efficacy of anti-HER2 CAR-TILs in mice and dogs, showing tumor eradication and tolerability.

bioRxiv · Sep 11, 2022Cancer Biology

Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in uveal melanoma

V. R. Sah, H. Jespersen, J. Karlsson, M. Lindberg, L. M. Nilsson, L. Ny, J. A. Nilsson

This study investigates enhancing PD-1 inhibitor efficacy in uveal melanoma through epigenetic modulation with HDAC or BET inhibitors, finding that HDAC inhibition synergizes with immunotherapy.

bioRxiv · Feb 4, 2021Cancer Biology

Small molecule inhibitors and a kinase-dead expressing mouse model demonstrate that the kinase activity of Chk1 is essential for mouse embryos and cancer cells

S. V. Muralidharan, L. M. Nilsson, M. F. Lindberg, J. A. Nilsson

bioRxiv · Jan 21, 2020Cancer Biology

BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant glioma

E. Funck-Brentano, D. Vizlin Hodzic, J. A. Nilsson, L. M. Nilsson

The paper identifies that BET bromodomain inhibitors like HMBA synergize with MEK inhibitors to enhance apoptosis in glioma cells, both in vitro and in vivo.

bioRxiv · Jan 1, 2020Cancer Biology

Molecular profiling of driver events and tumor-infiltrating lymphocytes in metastatic uveal melanoma

J. Karlsson, L. M. Nilsson, E. M. Forsberg, S. Mitra, S. Alsen, G. Shelke, V. R. Sah, U. Stierner, C. All-Eriksson, B. Einarsdottir, H. Jespersen, L. Ny, P. Lindner, E. Larsson, R. Olofsson Bagge, J. A. Nilsson

This study profiles genomic and transcriptomic features of metastatic uveal melanoma, identifying BAP1 inactivation and immune checkpoint receptor expression in tumor-infiltrating lymphocytes.

bioRxiv · Aug 21, 2019Cancer Biology